What percent of that 91% of the trials that failed had virtually the same theory of approach to the disease? Don't you think that matters?

blu_1, your argument points towards possible side effects not rather the drug will work or not. I'll tell you what, if I had severe AD I would definitely take my chances with a drug that has possible seizures or possible psychiatric problems if it was proven to work. Wouldn't you? So a large market will be there.

I realize that it is the company officials job to say positive things about the company. And I also have been around long enough to know if that official is just doing his job or he truly believes what he is saying. I guess it's something that I can't explain.

Dr. Alkon used the terms " economical" and "easily scalable" when describing the new synthesis process of Bryostatin.

Companies usually can get a sense of how their trials are going even though they're blinded. The confidence Dr. Alkon has is infectious, you can hear it in his voice. If he sensed anything negative he would be hedging and pulling back in his tone. We got a winner here boys and girls. Imo!

GNMX formerly Medgenics. They have a glutaminyl cyclase inhibitor AD drug.

If the company feels they have a drug that can reverse the severe form of the disease, why bother with mild to moderate conditions who's results can easily be questioned. As Dr. Alkon said if the drug can treat severe cases it can treat mild and moderate.

It was recently mentioned on the board that we should be very cautious in expecting good results in Ntrp's upcoming trial data release. Mentioned were the recent failings of AD trails of GNMX and VTVT, but those companies were going after plaque. Has any drugs that regenerate neuronal synapses failed?

(Reply to previous response). Exactly runncoach. Dr. Alkon has computerized painstaking documentation that the synapses were regenerated. He's not guessing. It's proven in the preclinical animals and we can see it in the compassionate use patients. But I get what you're saying kld2.

Maybe I missed it, but why did the company decide not to blind the trial.

Ok. I can see that. Thanks runncoach, you too Wolf.

You said, "One problem is they just can’t short with any volume to knock the share price down." After seeing what they did last week, I would really hate to see if they had volume. But, I'm still not selling.

I like the benefits that uplisting brings to the stock, but I don't like the options availability that it may bring. Shorts can cover themselves. Would we qualify for options being sold?

Is vtvt going after plaque?

kld2, the way I see it, the 99.6% failure rate for AD trials only means that the bar is set really, really low for this trial. I love it.

The science hasn't changed. We know what we have, the shorts don't. If we don't sell they will be trapped. These are just games being played, don't let them scare you. If getting rich was easy everyone would be rich.

Wow!! After listening to Dr. Alkon's Sacks presentation, I'm mortgaging the house tomorrow.lol. Someone should send that video to A.F.

It does show 194M when I look it up. I guess it is only showing 1.41B in my portfolio list. It's never done that before.

Why does Yahoo Finance have Ntrp market cap at 1.41Billion? Did they do that on purpose?

Thanks, Wolf. I am still sure that I have either read or heard Dr. Alkon state that the company hopes that the trial produce results that causes the FDA to say that the results can't be sat on.

Most of the post was my opinion. The public statement was when Dr. Alkon said that the company hoped that the FDA would see the results and feel as though they can't sit on the results. I'm sure I'm not the only one that recall that statement.

No. When I said these are not verbatim quotes I was referring to statements make by the company publicly. I was just giving the just of what was said by the company, not exact. Also when I put quotations around saw and seen it could have been misunderstood. All of this is only my opinion.

But the company unofficially saw something in the trial way back in July that caused them to not want to tamper with the trial with the continuation changes of doses. They had "seen" enough. I believe that what the company "saw" was what Dr. Alkon was referring to with his statement that: The company hopes that when the FDA sees the results it will be something that the FDA will say "we can't sit on this...". (Please note these are not verbatim quotes.

Question: When was the trial results officially unblinded to the company?

For any poster on this board that believes that a company in Neurotrope's position can run a very short Ph2 trial, sense not good results coming and thus decides to cancel a planned continuation of the trial, please explain it to me.
That option would only be reserved for bigger companies with many other products to fall back on. This trail could be do or die for Neurotrope. The trial was very short. If they felt the results weren't going to be good they would continue it in hopes of maybe it needs more time.
Remember the company said the decision to cancel the continuation trial WAS NOT FOR SAFTY REASONS.

The bar is set so low for AD treatment trials and there is no existing affective treatments, why would you run an extended trial if you see the drug is working? Move on to Ph3.

Am I right in thinking the canceled "second exploratory study" is the same as the "open"extended trial?

Speculate. Why do you think the company filed to eliminate the second exploratory study? I say they saw excellent results and saw no need to try to improve on it, time is of the essence. If they weren't seeing good results they would have kept trying to improve the results.

Some people were feeling like that at $17.00 per share.

What would the needed liquidity be?

I think the shorts have not pounced on the stock because they are afraid of the uplisting. They don't know when it will happen and what it will bring forth.

Isn't compassionate use patient IV-18 Jenni? Also any information on the 95-year-old compassionate use Bahamian man?

Where can I find anything written about the other 3 compassionate use patients outside of Jenni?

If the company decides to raise money before data release, that will throw a monkey wrench in the creeping up of the s/p.

Just about all of the failed AD drugs would have answered yes to those questions. So what does that tell you?

But what are the chances of them raising before the uplisting to NASDAQ?

What are the chances of the company raising money before the uplisting?

New to the board, trying to catch up. When is the next AD update due for release? And what kind of info is expected? Is that the 3/31/17 date I'm hearing?

Thanks BioBull1, I don't think they will release the results of the vote until after the uplisting.

Thanks GentleGiant123, I appreciate the response.